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Abstract  
There are very few drug delivery systems that target key organs via the oral route, as 
oral delivery advances normally address gastrointestinal drug dissolution, permeation 
and stability. Here we introduce a nanomedicine, in which nanoparticles, while also 
protecting the drug from gastric degradation, are taken up by the gastrointestinal 
epithelia and transported to the lung, liver and spleen, thus selectively enhancing drug 
bioavailability in these target organs and diminishing kidney exposure (relevant to 
nephrotoxic drugs).  Our work demonstrates, for the first time, that oral particle uptake 
and translocation to specific organs may be used to achieve a beneficial therapeutic 
response.  We have illustrated this using amphotericin B, a nephrotoxic drug 
encapsulated within N-palmitoyl-N-methyl-N,N-dimethyl-N,N,N-trimethyl,6-O-
glycolchitosan (GCPQ) nanoparticles and have evidenced our approach in three separate 
disease states (visceral leishmaniasis, candidiasis and aspergillosis) using industry 
standard models of the disease in small animals.  The oral bioavailability of AmB-
GCPQ nanoparticles is 24%. In all disease models, AmB-GCPQ nanoparticles show 
comparable efficacy to parenteral liposomal AmB (Ambisome®). Our work thus paves 
the way for others to use nanoparticles to achieve a specific targeted delivery of drug to 
key organs via the oral route. This is especially important for drugs with a narrow 
therapeutic index. 
 
 
Keywords  
Amphotericin B, oral delivery, N-palmitoyl,N-methyl,N,N-dimethyl,N,N,N-trimethyl,6-
O-glycol chitosan, nanoparticles, nanomedicine  
Graphical abstract 
 
 
 
 
 
 
 
 
 
 
1. Introduction 
The oral administration of medicines is a preferred route of administration although a 
significant proportion of drugs are not orally bioavailable due to their physical 
properties, an issue which contributes to 40% of drug development failures 1. An 
industry, such as the pharmaceutical industry, which experiences 90% of clinical stage 
failures 2 and thus has to spend upwards of US$ 1 billion to develop a single new 
chemical entity medicine, requires new technologies that will enable medicine 
administration via the preferred route, regardless of the chemical features of any 
promising compounds. Oral drug delivery advances, to date, have focused on 
gastrointestinal drug dissolution 3, gastrointestinal drug permeability 4 and 
gastrointestinal compound stability 5.There are no technologies which have as their goal 
specific organ targeting via the oral route.  Our central hypothesis is that nanoparticles 
which target specific organs via the oral route will confer oral activity on drugs which 
are not otherwise active through this route. Targeting particular organs of pathology and 
avoiding sites of toxicity is the goal of drug delivery. Here we present a nanoparticle 
system that allows oral targeting to the organs of pathology, i.e. the lung, liver and 
spleen, via the oral route but avoids delivery to the organs of toxicity, the kidneys.  Such 
a system will be of particular relevance to nephrotoxic drugs. The utility of the system 
is illustrated via the use of amphotericin B (AmB), one of the most effective antifungal 
drugs used for the treatment of life-threatening systemic fungal infections such as 
candidiasis or aspergillosis and a drug that is also indicated for the treatment of visceral 
leishmaniasis 6, 7; the latter due to its very high cure rate and near absence of resistance.  
Intravenous administration of AmB marketed formulations (Fungizone®, Ambisome®, 
Abelcet® and Amphocil®) results in high drug levels in the target organs, i.e. the liver, 
spleen and lungs but also results in drug accumulation in the kidney, leading to toxicity, 
as the drug is nephrotoxic. Both nephrotoxicity and infusion-related side effects, such as 
infections, thrombophlebitis, fever, chills, vomiting, headaches and haemolysis limit the 
usefulness of parenteral AmB formulations. Furthermore, the requirement for 
hospitalisation during treatment, hampers access to parenteral AmB, especially in low 
resource environments such as developing countries 7, 8. To date, no oral AmB 
formulations have been marketed because of AmB’s poor gastrointestinal solubility and 
permeability 9, 10. Therefore, developing an oral AmB formulation is a viable means of 
improving patient access to treatment worldwide.   
N-palmitoyl-N-monomethyl-N,N-dimethyl-N,N,N-trimethyl-6-O-glycolchitosan 
(GCPQ) is a self-assembling nanoparticle forming polymer that is taken up by 
enterocytes and enables the bioavailability of hydrophobic drugs and peptides11-14.  Our 
oral drug organ targeting hypothesis will be tested by encapsulating AmB in GCPQ 
nanoparticles and studying drug and particle biodistribution and drug pharmacological 
efficacy in comparison to control nanoparticle systems: i.e., AmB liposomes 
(Ambisome®) or AmB deoxycholate micelles (AMBd). 
 
 
 
 
 
 
 
2. Experimental section 
2.1. Polymer synthesis and characterization 
GCPQ and deuterated GCPQ were synthesized and characterised as previously 
described11-13, 15, 16. Nuclear Magnetic Resonance (1H NMR) experiments were 
performed to determine the degree of substitution of the polymer. The level of 
palmitoylation was calculated as the ratio between palmitoyl methyl protons (δ= 1.30-
1.40) and sugar methine/methylene protons (δ= 3.5-4.5). The level of quaternization 
was calculated based on the ratio of quaternary ammonium methyl protons (δ= 3.4) to 
sugar methine/methylene protons (δ= 3.5-4.5). The Hydrophobicity Index (HI) was 
calculated as the ratio between palmitoylation (mole %) and quaternary ammonium 
groups (mole%). Gel Permeation Chromatography- Multiangle Laser Light Scattering, 
Fourier-Transformed Infrared spectroscopy (FTIR), Transmission Electron Microscopy 
(TEM), Photon Correlation Spectroscopy (PCS), Spontaneous Raman Scattering 
Spectroscopy and Multimodal Multiphoton Microscopy were used in the 
characterization and imaging of the polymer. See Supplementary Information for further 
details. 
2.2. Preparation, characterization, dissolution and stability studies of AmB-
GCPQ nanoparticles 
Polyelectrolyte complex formation. AmB was solubilised through the formation of 
carboxylate salts at the concentration of 4 mg mL-1 in sodium hydroxide (0.02 N) at pH 
12. GCPQ (20 mg mL-1) was added to the solution. Polyelectrolyte complexes were 
formed between the carboxylic groups of the AmB and the positively charged 
quaternary ammonium groups of the GCPQ.  The final pH of the dispersion was 
reduced to pH = 5. AmB-GCPQ nanoparticles were centrifuged (13000 rpm, 30 min, 
Microcentaur, MSE, London, U.K.) to remove any aggregated polymer or undissolved 
drug and the supernatant was collected and characterised by PCS, FTIR and TEM. AmB 
aggregation state was assessed by UV. 
Isocratic HPLC quantification of AmB. A validated analytical method utilising an 
Agilent 1200 series HPLC was used 17. See Supplementary Information for method 
details.  
Flow-through cell dissolution study (USP 4). A flow-through cell dissolution 
apparatus in an open-loop configuration and a cell of an internal diameter of 22.6 mm 
were used.  Please see Supplementary Information Figure S1 for a schematic 
representation of the equipment used. The bottom cone of the cell was filled with one 5 
mm diameter bead positioned at the apex, followed by 7 g of 1 mm diameter glass beads 
in order to generate a laminar flow. A NPcapsTM nº2 capsule (gelatin-like performance 
capsules made of Pullulan) filled with lyophilised formulation [either AmB-GCPQ or 
AmB deoxycholate (AMBd)] containing 5 mg of AmB was placed on the top of the 
small beads. A #40 mesh screen, a glass microfiber filter (Whatman® GF/D, 2.7 μm) 
and a 0.45 μm HA (mixed cellulose esters) hydrophilic filter (Millipore®) were 
positioned at the inner top of the cell to retain undissolved material. The dissolution 
medium was circulated by pumping it through the cell at a flow rate of 6 ml min-1. 
Three dissolution media prepared as described in the US Pharmacopeia 18 were used 
during the experiment: simulated gastric fluid without enzymes (pH = 1.2) from 0 to15 
min, acetate buffer (pH = 4.5) from 15 to 30 min and simulated intestinal fluid without 
enzymes (pH = 6.8) from 30 to 240 min. The temperature was maintained at 37 ± 0.5°C 
during testing. Samples were collected from the flow-through cell in fractions and 
scanned between 300 – 450 nm (Shimadzu UV-1700 spectrophotometer, Shimadzu, 
Kyoto, Japan). Calibration curves were prepared using each of the dissolution media. 
The sum of the absorbance values at 406 and 328 nm (corresponding to the λmax of the 
monomeric and dimeric AmB form respectively) was used to calculate the percentage of 
drug dissolved at each time point. 
Long term stability studies. Stability studies were performed according to the 
International Conference on Harmonisation (ICH) guidelines Q1A (R2) [Stability 
testing of new drug substances and products] at 5°C ± 3°C for 12 months. NPcapsTM nº2 
capsules were filled with 5 mg of lyophilised AmB-GCPQ formulation. Filled capsules 
were packaged in a blister made of poly(vinyl chloride) (PVC) with aluminium foil. At 
various time intervals, the contents of each capsule were dispersed in deionised water 
(at 1 mg mL-1) and drug content and particle size were recorded (please see 
Supplementary Information for method details). 
2.3. Pharmacokinetic studies in murine model 
All experiments were performed under a UK Home Office Animal License. 
Single dose oral administration of AmB formulations. CD-1 mice were randomly 
split into groups (n= 4), fasted overnight and then administered AmB formulations by 
oral gavage.  Three different formulations of AmB were administered at an AmB dose 
of 5 mg kg-1 at the concentration of 1 mg mL-1: (i) AmB-GCPQ (1: 5 g g-1), (ii) AMBd 
(AmB, sodium deoxycholate, 1: 0.82 g g-1, please see Supplementary Information for 
the preparation method) and (iii) AmB in 5% dextrose. Mice were sacrificed at different 
time points (0.5, 2, 4, 8, and 24 h) and blood and other organs (liver, spleen, brain, 
lungs, kidneys, bladder and gall bladder) were harvested. Plasma was separated by 
centrifugation (4500 rpm, 15 min, 4 °C, Hermle Z323K centrifuge, VWR, Poole, U.K.) 
and all tissues were stored at – 20 °C until analyses could be performed on them. 
Multiple dose oral administration of AmB-GCPQ formulation. CD-1 mice were 
randomly divided into two groups (n = 3), fasted overnight and administered AmB by 
oral gavage.  Oral gavages of AmB-GCPQ (1: 5 g g-1) were administered at an AmB 
dose of 5 mg kg-1 and a concentration of 1 mg mL-1 for 5 days either twice daily (Group 
A) or once a day (Group B). Mice were sacrificed either 12 h (Group A) or 24 h (Group 
B) following the last administration of AmB-GCPQ. Blood and tissues (brain, liver, 
spleen, lungs, kidneys, bone marrow, bladder and gall bladder) were collected and 
stored as described above until samples could be analysed. 
Intravenous (i.v.) administration of AmB-GCPQ formulation. Groups (n = 3) of 
male BALB/c mice were intravenously administered a freshly filtered (0.2 µm) AmB-
GCPQ formulation (1: 5 g g-1) at an AmB dose of 1 mg kg-1. The formulation was 
previously diluted to 0.25 mg mL-1 with a solution of (1: 1) of sodium chloride (0.9% 
w/v) and dextrose (5% w/v). At various time intervals, animals were sacrificed (5 min, 
30 min, 2 h, 4 h, 8 h, and 24 h) and blood was sampled. Plasma was separated and 
stored as described above.  
AmB extraction. Plasma samples (100 μL) were spiked with the internal standard 
meloxicam (Fagrón SL., Madrid, Spain, 200 μg mL-1, 10 μL) to a final concentration of 
20 μg mL-1. Extraction was carried out with methanol (300 μL). After vortexing, the 
mixture was centrifuged (10000 rpm, 10 min, Microcentaur, MSE, London, U.K.) and 
the supernatant evaporated to dryness under a stream of nitrogen. The samples were 
reconstituted in methanol (100 μL) and then centrifuged again (9000 rpm, 5 min, 4°C). 
The supernatants were analysed by the isocratic HPLC method previously described. 
Tissue samples (liver, brain, kidneys, spleen, lungs and bone marrow) were added to 
sodium hydroxide solution (0.02 M) at pH 12 at a concentration of 0.5, 0.5, 0.25, 0.1, 
0.1 and 0.1 g mL-1 tissue respectively homogenised. These tissue homogenates were 
spiked with meloxicam (10 μg mL-1, 400 μL) as described above. Two extractions of 
the aqueous tissue homogenate were carried out with methanol (2 mL x 2). After every 
extraction, the mixture was vortexed and then centrifuged (9000 rpm, 20 min, 4 °C). 
The supernatant (2 mL x 2) was collected and then evaporated to dryness under a stream 
of nitrogen. The samples were reconstituted with methanol, mobile phase (1: 1, 200 µL) 
consisting of acetonitrile, acetic acid, water (52: 4.3: 43.7, v/v/v)). After reconstitution, 
samples were centrifuged (13000 rpm, 5 min) and the supernatants analysed using a 
gradient HPLC method.  
Urine was obtained after centrifuging bladder samples (13000 rpm, 5 min) Urine 
samples (10 µL) were spiked with meloxicam (200 µg mL-1, 10 µL) and to this was 
added methanol (80 µL). Similarly, bile samples (the whole gallbladder) were spiked 
with meloxicam (200 µg mL-1, 10 µL) and to this was added methanol (100 µL). After 
vortexing, samples were centrifuged (13000 rpm, 10 min) and the supernatants were 
analysed by a gradient HPLC method. 
Gradient HPLC quantification of AmB. An HPLC gradient method utilising an 
Agilent 1200 series HPLC was developed to analyse the tissue samples. The samples 
(40 µL) were chromatographed over a Thermo Hypersil BDS C18 reverse-phase 
column (200 × 4.6 mm, 5 μm) maintained at 40°C, at a flow rate of 1.2 mL min-1. The 
mobile phase consisted of 0.02 %w/v trifluoroacetic acid in water (line A) and 
acetonitrile (line B). The gradient method expressed as time (min): line B (%) was the 
following one: 0:10, 5:10, 15:59, 22:66, 28:90, 33:10. AmB and meloxicam were 
detected at a wavelength of 406 nm and their retention times were 16.0 and 16.6 min 
respectively. AmB concentrations were calculated from linear regression calibration 
curves from peak height ratios of AmB/ meloxicam. 
2.4. Oral pharmacokinetic studies in beagles 
All experiments were approved and performed in accordance with local ethics 
committee rules (University Cardenal Herrera-CEU, Valencia, Spain). 
Animals. Healthy beagle dogs were housed according to the standards of the 
Committee of Animal Welfare, fed daily, and allowed free access to water throughout 
the study. Animal groups consisted of four male beagle dogs (weight = 15 - 19 kg) and 
one female beagle dog (weight = 15 kg), all of approximately 4 years of age.  
Single dose oral administration of AmB formulations. Dogs were randomly assigned 
to receive orally either AmB-GCPQ formulation (n=3) or liposomal AmB 
(AmBisome®) (n=2) at 4 mg kg-1 of body weight. Prior to administration, AmBisome® 
was reconstituted with 5% w/v glucose at a final concentration of 4 mg mL-1. AmB-
GCPQ was prepared as previously described at a final AmB concentration of 4 mg mL-
1. After oral administration, blood sampling was carried out at time zero (predose), 15 
min, 30 min, 60 min, 90 min, 2 h, 4 h, 6 h, 8 h, 24 h and 48 h. Plasma was separated by 
centrifugation and then stored at -20 ºC until analyses could be performed. 
Extraction of AmB. Plasma samples (250 μL) were spiked with meloxicam (250 μg 
mL-1, 10 μL) to a final concentration of 10 μg mL-1. Two extractions were carried out 
with methanol (750 μL x 2), followed by a third extraction with acetonitrile (750 μL). 
After every extraction, the mixture was vortexed and centrifuged (9000 rpm, 10 min, 
4°C). The supernatants were pooled (750 μL x 3) and, evaporated to dryness in a 
concentrator (Savant, SpeedVac®, Holbrook, NY, USA) at 30°C. Samples were 
reconstituted with a methanol, mobile phase solution (1:1, 250 μL).  The mobile phase 
consisted of acetonitrile, acetic acid, water (52: 4.3: 43.7, v/v/v). The reconstituted 
samples were centrifuged (9000 rpm, 5 min, 4°C) and the supernatants were analysed 
by the isocratic HPLC method previously described 17.  
2.5. Efficacy study in a systemic murine model of visceral leishmaniasis 
Animals. BALB/c mice (20-25 g) were randomly split into 5 groups (n = 8) and 
allowed food and water ad libitum. All experiments were approved by the Complutense 
University of Madrid Institutional Animal Care and Ethics Committee. 
Infection. The preparation of the parasites and the experimental infection were 
performed as previously described 19. Please see Supplementary Information for further 
details. Each animal was infected with 107 promastigotes by intracardiac injection. 
Treatment. All treatments started on day 24 post-infection. Group A received 
intraperitoneal (i.p.) AmBisome® at a single dose of 5 mg kg-1. Prior to administration, 
AmBisome® was reconstituted with water for injection to an AmB concentration of 4 
mg mL-1 and then further diluted with glucose (5% w/v) to a final concentration of 1 mg 
mL-1. Group B received an oral (p.o.) dose of the AmB-GCPQ formulation (AmB, 
GCPQ, 1: 5 g g-1) at a dose of 5 mg kg-1 daily for five consecutive days. Group C served 
as an untreated control for groups A and B. Group D was treated orally with the same 
formulation as group B (AmB-GCPQ) at a dose of 5 mg kg-1 daily for ten consecutive 
days. Group E served as an untreated control for group D. Animals were sacrificed on 
day 31 (groups A, B and C) or day 36 (groups D and E) post- infection. Spleens and 
livers from each animal were aseptically removed and weighed to quantify the parasite 
burdens. Plasma and kidneys were collected to quantify the concentration of AmB. 
Plasma was separated by centrifugation and then both the plasma and kidneys were 
stored at -20 ºC until they could be analysed. 
Tissue burden. The parasite burden was quantified by the limit dilution assay as 
described previously 20, 21. Please see Supplementary Information for further details. 
The percentage suppression of parasite replication (PS) was calculated using the 
following modified equation of Manandhar et al.22: 
PS = (PC-PT) / PC x 100   (Equation 1); 
where PC is the number of parasites in the control group per tissue weight (g) and PT is 
the number of parasites after treatment per tissue weight (g). 
Pharmacokinetic studies. Plasma and kidney samples were analysed as described 
above for the quantification of AmB in tissues. 
2.6. Efficacy study in a systemic murine model of aspergillosis 
Animals. Four week old OF-1 male mice (weight = 30 g) allowed food and water ad 
libitum were used. Animals were immunosuppressed one day before infection by a 
single i.p. dose of cyclophosphamide (200 mg kg-1) and a single intravenous (i.v.) dose 
of fluorouracil (150 mg kg-1). All experiments were approved by the Universitat Rovira 
i Virgili Institutional Animal Care and Ethics Committee.  
Infection.  One clinical isolate of Aspergillus fumigatus (FMR 7739) showing an AmB 
minimum inhibitory concentration of 1 µg ml-1 (determined by following Clinical and 
Laboratory Standards Institute guidelines) was used. The fungus was grown on potato 
dextrose agar (PDA) for 5 days at 35 ºC until sporulation occurred. The inoculum was 
prepared by flooding the plate surface with saline solution. The fungal suspension was 
filtered twice through sterile gauze to remove hyphae and clumps of agar and adjusted 
to the desired concentration by haemocytometer counting. To verify the viability and 
size of the inocula, 10 fold dilutions were placed in PDA for colony forming units 
(CFU) determination. Animals were challenged i.v. via the lateral tail vein with a 
conidial suspension containing 1x104 CFU in 0.2 ml of saline solution. 
Treatment All treatments were started 24 h post infection and lasted for 10 days. Prior 
to administration, formulations were reconstituted with water for injection to an AmB 
concentration of 4 mg mL-1 and then further diluted with glucose (5% w/v) to a final 
concentration of 1 mg mL-1. In the first experiment, groups of animals (n = 10) received 
AmBisome® administered i.v. at a dose of 5 mg kg-1 day-1, AMBd administered i.v. at a 
dose of 0.8 mg kg-1 day-1, AMBd administered p.o. at 5 mg kg-1 day-1 or AmB-GCPQ 
administered p.o. at 5 mg kg-1 day-1. In the second experiment, groups of animals (n = 
15) received AmBisome® administered i.v. at 2.5 mg kg-1 day-1, AMBd administered 
i.v. at 0.5 mg kg-1 day-1, AMBd administered p.o. at 2.5 mg kg-1 day-1 or AmB-GCPQ 
administered p.o. at 2.5 mg kg-1 day-1. In the third experiment, groups of animals (n = 
15) received AmBisome® administered i.v. at 5 mg kg-1 day-1, AMBd administered i.v. 
at 0.8 mg kg-1 day-1, AmB-GCPQ administered p.o. at 7.5 mg kg-1 day-1 or 15 mg kg-1 
day-1. One group without treatment was included as a control in all the experiments. 
Tissue burden Eight days post infection, 5 animals from each group were sacrificed. 
Kidneys and lungs were removed, mechanically homogenized in 0.9% saline, diluted 
ten-fold in 0.9% saline and the homogenate placed on PDA plates for CFU g-1 
determination.  
2.7. Efficacy study in a systemic murine model of candidiasis 
Animals. Male BALB/c mice were randomly split into 3 groups (n = 5) and allowed 
food and water ad libitum. All experiments were approved by the Complutense 
University of Madrid Institutional Animal Care and Ethics Committee. 
Infection. One clinical isolate of Candida albicans CECT 1394 was used. Cultures 
were grown on Sabouraud dextrose agar for 48 h at 30 °C. A colony was resuspended in 
Yeast Extract Peptone Dextrose (YPD) broth (100 mL) and incubated at 30°C 
overnight. The log-phase Candida suspension was centrifuged (3000 rpm, 10 min, 4°C), 
washed two times with phosphate-buffered saline (PBS) and diluted to a final 
concentration of 20 x 106 CFU mL-1. BALB/c mice were inoculated i.v. via the lateral 
tail vein with 1 x 106 CFU in PBS (50 µL). 
Treatment. Treatment started 24 h following infection and lasted for 9 days. Prior to 
administration, formulations were reconstituted with water for injection to an AmB 
concentration of 4 mg mL-1 and then further diluted with glucose (5% w/v) to a final 
concentration of 1 mg mL-1.  Groups (n = 5) were treated either with AmB-GCPQ p.o. 
at 5 mg kg-1 day-1 or Ambisome® i.p. at 3 mg kg-1 day-1. Another group of mice treated 
p.o. with deionized water: 5% glucose (1: 3) was included as a control.  
Tissue burden. Mice were sacrificed by chloroform inhalation at day 10 post-infection 
and target organs (kidneys, liver, lung, brain and spleen) were removed aseptically, 
weighed, and homogenized in sterile saline (5 ml g-1 tissue). The number of CFU was 
determined by a plate dilution method in duplicate using yeast extract dextrose 
chloramphenicol agar and colony counting was performed after 72 h of incubation at 30 
°C. 
Toxicological and pharmacokinetic studies. Blood samples were collected at day 10 
post-infection and serum was separated by centrifugation (3000 rpm, 10 min, 4°C). 
Samples were stored at −20°C for biochemistry analysis including creatinine, urea, 
alkaline phosphatase, aspartate transaminase (AST), alanine transaminase (ALT) and 
bilirubin. Samples from healthy mice were included as controls. For pharmacokinetic 
studies, AmB concentrations in kidney, liver, brain and spleen were determined. 
2.8. Statistical analysis 
Statistical analyses were performed via one-way ANOVA Test using Minitab 15 
(Minitab Ltd, Coventry, UK) followed by Tukey’s test.  Statistical significance was set 
at a p < 0.05.    
  
3. Results 
3.1. AmB-GCPQ interaction 
GCPQ (Mw = 9,955 Da, Mn = 9,135 Da, Mw/Mn = 1.090, dn/dc = 0.1355 ± 0.0028 mL 
g-1, 16.9 mole % palmitoylation and 16.5 mole % quaternary ammonium groups, HI = 
1.02) was synthesised and characterised. The FTIR spectrum shows the interaction 
between AmB and GCPQ (Figure 1a) with an electrostatic complex being formed. This 
is evidenced by the fact that the signal from the carboxylate groups of the AmB at 1691 
cm-1 (C=O stretch) disappears as does the C-N stretch signal from the GCPQ quaternary 
ammonium group (1246 cm-1). The molar ratio of hydrophobic to hydrophilic groups 
(HI) in GCPQ plays a crucial role in its complexation with AmB. Polymers with higher 
palmitoylation (> 25%) or lower quaternization (< 15%) failed to form nanosized 
complexes and resulted in a liquid containing larger (> 1 μm) aggregates.   
In aqueous environments, GCPQ self-assembles to form polymeric micelles with a 
particle size of between 5 – 30 nm in diameter while AmB itself aggregates forming 
insoluble polyhedral crystals (see Supplementary Information Figure S2). The AmB, 
GCPQ interaction resulted in the solubilisation of AmB crystals followed by the 
formation of highly stable nanoparticles characterised by a particle size of 216 and 35 
nm (Figure 1b). The biomodal size is due to an equilibrium being established between 
drug filled particles and empty micelles.  The particles have a core shell structure with 
the ionic units (and hence dark stained areas) forming the particle shells and the 
hydrophobic groups (white stain free areas) forming the particle core (Figure 1 b). The 
polar head of the AmB molecules will be oriented to the aqueous phase and the 
hydrophobic tail to the core of the nanoparticles. The hydrophobic tail of the polymer 
has the same number of carbons as the hydrophobic domain of AmB which should 
enhance the hydrophobic interaction (see Supplementary Information Figure S2). The 
amount of amphotericin B loaded in nanoparticles was 90% as quantified in the 
supernatant obtained after centrifugation. Dimers and monomers of AmB were 
encapsulated in the polymer exhibiting characteristic absorption peaks at  328, 363, 383 
and 407 nm and resulting in a transparent yellow liquid 7. 
Lyophilised AmB-GCPQ nanoparticles exhibited good long term stability when stored 
at 5 ± 3 °C (particle size and drug content remained unaltered over one year, See 
Supplementary Information Figure S3) and these particles significantly enhanced AmB 
dissolution in simulated gastrointestinal fluids when compared to AMBd (Figure 1c). 
 Figure 1. AmB-GCPQ interaction. (a) FTIR spectrum of AmB raw material, GCPQ 
and AmB-GCPQ nanoparticles after freeze drying. Key:  - stretching vibrations; δ – 
bending vibrations. (b) TEM with negative staining of AmB (8 mg mL-1)-GCPQ (40 mg 
mL-1) nanoparticles in deionized water. (c) Dissolution profile of AmB-GCPQ 
nanoparticles (-□-) versus AMBd (-■-). 
 
3.2. Drug Pharmacokinetics 
Mouse plasma and tissue concentration, time profiles of AmB following a single oral 
administration of AmB-GCPQ, AMBd or AmB in dextrose are shown in Figures 2a - e. 
Formulation characterisation data and pharmacokinetics parameters may be found in 
Supplementary Information Tables S1 and S2.  With all formulations AmB plasma 
concentrations increased slowly and were sustained for 8 h after (Figure 2a).  However 
the drug was largely tissue bound and accumulated in the liver, spleen and lung (Figure 
2b, 2c, 2d). AmB-GCPQ resulted in higher plasma levels when compared to AmB in 
dextrose.  Significantly higher AmB levels were found in the liver when the particulate 
formulations of AmB (AmB – GCPQ and AMBd) were administered compared to AmB 
in dextrose (Figure 2b).  Significantly higher levels of AmB were found in the lungs and 
spleen, after oral administration of AmB-GCPQ compared to the administration of 
AmB in dextrose and AMBd.  Only minor differences were found in AmB kidney 
levels, with respect to the formulation administered (Figure 2e). As AmB is a 
nephrotoxic drug, target organ, kidney ratios are crucial.  Lung, kidney AUC0-24 ratios 
for AmB-GCPQ and AMBd were 1.44 and 0.86 respectively while the corresponding 
spleen, kidney ratios were 1.22 and 0.81 respectively and the corresponding liver, 
kidney ratios were 0.88 and 0.40 respectively.  These data demonstrate that, when 
compared to the deoxycholate micelles, GCPQ nanoparticles delivered relatively more 
drug to the target organs (liver, lung and spleen) than was delivered to the kidney.  This 
finding is further confirmed by lower urine levels of AmB with the oral AmB-GCPQ 
formulation (Supplementary Information Figure S4a).  The AmB in dextrose 
formulation delivered the most drug to the kidneys at the early time points, showing the 
drug in solution is rapidly eliminated by the kidneys; a fact that could contribute to the 
occurrence of nephrotoxicity and would explain the reduced drug levels in the target 
organs with the AmB in dextrose formulation. AmB was also recovered from the gall 
bladder, reaching a maximum concentration at 4 hours following oral administration 
(see Supplementary Information Figure S4b). This is evidence of enterohepatic 
circulation of the drug.  After 4 h, AmB levels in the bile decreased as a result of the 
animals being fed.  The percentage of the AmB dose recovered from tissues (liver, 
spleen, lungs, kidneys) and plasma, 8 h after dosing the AmB-GCPQ formulation was 
2.3%, which is 2-fold higher than when the drug was administered orally in dextrose.  
After the administration of multiple doses of AmB-GCPQ to mice, AmB accumulated 
in the target organs (lungs, liver and spleen) and to a lesser extent in the kidney (Figure 
2f and Supplementary Information Table S2).  AmB-GCPQ also delivered AmB to the 
bone marrow and brain; the former important for the clearance of Leishmania and the 
latter important for the targeting of systemic fungal infections. AmB bile levels, 
following multiple doses, were significantly enhanced when compared to urine levels, 
further confirming a major role for enterohepatic circulation in AmB-GCPQ’s delivery 
mechanism.  
When a single dose of AmB-GCPQ was administered to dogs, again oral absorption 
was sustained for up to 8 h (Figure 2g).  Plasma levels in dogs with oral AmB-GCPQ 
were over two fold higher than plasma levels seen with the oral administration of a 
nanoparticle formulation – AmBisome®.  With AmB-GCPQ the plasma half-life (t1/2) 
was 59.2 h in dogs and drug was still detectable in the plasma 48 h after dosing, 
whereas it was not detectable 48 h after dosing with oral AmBisome® in dogs. Both 
formulations were well tolerated and there were no signs of gastrointestinal toxicity 
(vomiting or diarrhoea). 
After i.v. administration of AmB-GCPQ (Figure 2 h), there was a fast decline in the 
AmB plasma level, followed by a slower disappearance of the drug from the plasma 
compartment as it equilibrates with the tissue bound drug.  Similar high AmB tissue 
distributions have been observed by others 23, 24. The absolute oral bioavailability of 
AmB-GCPQ was 24.7%. Similar oral bioavailability values have been reported for plain 
GCPQ nanoparticles16. The plasma t1/2 of the AmB-GCPQ formulation in mice was 61.3 
h. 
 
 
  
 
 
 
 
 
 
 
 
 
  

Figure 2. Pharmacokinetic studies: oral AmB translocation to major target organs. 
(a-e) Single dose oral administration of AmB formulations at 5 mg kg-1 in CD-1 
mice. Key: AmB in dextrose (-■-); AMBd (-▲-); AmB (5 mg kg-1)- GCPQ (25 mg kg-
1) formulation (-●- ). (a) AmB plasma levels (µg mL-1). (b) AmB concentration in liver 
(µg g-1).  (c) AmB concentration in spleen (µg g-1).  (d) AmB concentration in lungs (µg 
g-1).  (e) AmB concentration in kidneys (µg g-1). Statistical significant differences: * = p 
< 0.05 AmB-GCPQ versus AmB in dextrose; # = p< 0.05 AmB-GCPQ versus AMBd; + 
= p< 0.05 AmB in dextrose versus AMBd. (f) Multiple dose oral administration of 
AmB-GCPQ. AmB concentration in plasma and tissue distribution in major target 
organs after single and multiple dose administration in CD-1 mice. Key: AmB 
concentration at 24 hours after single oral administration of AmB-GCPQ formulation 
(at 5 mg kg-1) (white); AmB concentration at 24 hours following the completion of once 
daily for 5 days oral treatment course of 5 mg kg-1 of AmB-GCPQ formulation (grey); 
AmB concentration at 12 hours following the completion of twice-daily for 5 days oral 
treatment course of 5 mg kg-1 of AmB-GCPQ (black). AmB levels in bone marrow 
(BM) after single oral administration were not quantified. Statistical significant 
differences: * = p < 0.05 versus oral single dose administration and # = p< 0.05 
mutidose once-daily versus multidose twice-daily administration. (g) AmB oral 
administration in beagles. Key: AmB plasma concentration (mean ±SD) versus time 
profile after a single oral administration of AmBisome® (4 mg kg-1) (-♦-) and AmB (4 
mg kg-1)- GCPQ (20 mg kg-1) nanoparticles (-■-) in beagles.  AmB plasma 
concentration at 48 hours after orally administered AmBisome® was below the 
quantification limit of our method (15 ng mL-1). Statistical significant differences: * = p 
< 0.05 AmB-GCPQ versus AmBisome®. (h) AmB oral bioavailability. AmB plasma 
concentration (mean ±SD) versus time profile after oral (-●-) and iv (-■-) administration 
of AmB-GCPQ formulation at the dose of 5 and 1 mg kg-1 respectively. 
 
3.3. Oral Particle Translocation to Major Organs 
The coherent anti-stokes Raman spectroscopy (CARS) method used, images highly 
concentrated species in a narrow focal area and only reports a signal for a self-
assembled nanoparticle and not for individual polymer molecules as it is only with the 
former that the finite local concentrations are high enough to cross the resolution 
threshold for the technique. Using multimodal imaging techniques, deuterated GCPQ 
nanoparticles were imaged in the liver (Figure 3a), lungs (Figure 3b) and intestine 
(Figures 3c – e). Within the liver, GCPQ nanoparticles were located in the hepatocytes, 
the intercellular spaces between hepatocytes and bile canaliculi (Figure 3a); this is 
indicative of enterohepatic circulation and explains the prolonged oral absorption phase 
(Figure 2a).  The presence of GCPQ particles in the liver (Figure 3a) and lung (Figure 
3b) is explained by the fact that GCPQ particles are absorbed via the enterocytes as they 
were found within the intestinal villi (Figure 3c), from where they accessed the liver via 
the portal vein and systemic circulation and accessed the lung via the systemic 
circulation.  GCPQ nanoparticles are not only taken up by the enterocytes but are also 
taken up by the Peyer’s patches (Figure 3e) where they would have access to the 
systemic circulation via the lymphatic vessels.   GCPQ nanoparticles are mucoadhesive 
12 and they were found in the Brunner’s glands of the duodenum (Figure 3d); the main 
function of the Brunner’s glands is the secretion of a mucus-rich alkaline secretion into 
the duodenum.   Please see Supplementary Information Figure S5 and Video 1 for 
additional details.    
 Figure 3. Multimodal multiphoton microscopy: oral AmB translocation to major 
target organs at 4 h after administration. (a) Liver. Three-dimensional multiphoton 
image reconstructions obtained from a liver sample. Two photon fluorescence (red) was 
used to generate contrast from endogenous fluorophores such as NADH, in addition to 
aldehyde-induced fluorescence from Schiff bases formed from the reaction of aldehydes 
reacting with the tissue proteins’ epsilon amino groups. Second harmonic generation 
provided contrast from collagen (blue). Contrast from deuterated particles was obtained 
with epi-detected CARS exciting the C-D resonance at 2100 cm-1 (green). The location 
of the deuterated particle signal is denoted by yellow arrows. (b) Lungs. Three-
dimensional reconstructions of multiphoton images obtained from a lung sample. Red 
contrast was obtained from structures rich in C-H bonds, such as lipid droplets and cell 
membranes, using epi-detected CARS with the pump and Stokes beams tuned to excite 
the CH2 resonance (2845 cm-1). Green contrast was obtained from deuterated particles 
with epi-detected CARS exciting the C-D resonance at 2100 cm-1. (c) Small intestine. 
Three-dimensional reconstructions of multiphoton images obtained from a small 
intestine sample. Two photon fluorescence (red) – exciting contrast from endogenous 
fluorophores such as NADH, in addition to aldehyde-induced fluorescence from Schiff 
bases formed from the reaction of aldehydes reacting with the tissue proteins’ epsilon 
amino groups. Green contrast was obtained from deuterated particles with epi-detected 
CARS exciting the C-D resonance at 2100 cm-1. Within the villus cross sections, it is 
possible to see deuterated GCPQ has crossed the enterocyted (ii, iii and iv). Deuterated 
GCPQ signal is also found in association with mucus above the villi’s surface in the 
three-dimensional reconstruction in (i). (d) Brunner’s gland. Three-dimensional 
multiphoton image reconstruction of Brunner’s glands. Red contrast was obtained from 
structures rich in C-H bonds, such as lipid droplets and cell membranes, using epi-
detected CARS with the pump and Stokes beams tuned to excite the CH2 resonance 
(2845 cm-1). Green contrast was obtained from deuterated particles with epi-detected 
CARS exciting the C-D resonance at 2100 cm-1. Blue contrast arises from SHG of 
collagen within the sample. (e) Peyer’s patch. i) Transmitted light image at low 
magnification, illustrating a Peyer’s patch and surrounding villi. ii – vi) Epi-detected 
CARS image composites (red shows contrast from the CH stretch obtained with the 
pump and Stokes beams tuned to 2855 cm-1, green shows contrast from the CD stretch 
obtained with the pump and Stokes beams tuned to 2100 cm-1.) ii and iii were taken at 
the surface of the Peyer’s patch, with M-cells and goblet cells marked with ‘M’ and ‘G’ 
respectively on B. iv was taken 14 microns below the surface, in the region outlined 
with a yellow box on iii. The cell outlined with a yellow box in iv is shown in more 
detail in v and vi, in three-dimensional composites of the CARS depth stack, illustrating 
the distribution of dGCPQ within this cell.  
 
3.4. Efficacy in visceral leishmaniasis 
The oral administration of AmB-GCPQ nanoparticles at 5 mg kg-1 day-1 for 10 days was 
similarly efficacious, in a murine model of visceral leishmaniasis, as a parenteral dose 
of AmBisome® (Figure 4).  No statistical significant differences were observed between 
both therapies in the inhibition of parasite replication in liver (98.9% and 99.8%) and in 
spleen (92.1% and 95.2%) respectively. However, oral administration of AmB-GCPQ 
for only 5 days was not sufficient to reduce parasite replication being less effective than 
parenterally administered AmBisome® (data no shown).   
 
Figure 4. Antileismanial activity of oral AmB-GCPQ nanoparticles in L. infantum-
infected BALB/c mice. All treatments started 24 days post-infection. Groups of 
animals (n = 8) received either AmBisome® i.p. at a single dose of 5 mg kg-1 body 
weight or orally AmB-GCPQ formulation at 5 mg kg-1 once-daily for 10 consecutive 
days. The parasitic burden was estimated by the limit dilution assay. Key: percentage of 
suppression of parasite replication in liver (grey) and spleen (white). Data are expressed 
as mean ± SD. Statistical significant differences (p < 0.05) were not found between both 
regimens. 
 
AmB plasma levels 7 days after a single i.p. dose of Ambisome® (at 5 mg kg-1), 3 days 
after the last oral dose of  AmB-GCPQ 10 day course (at 5 mg kg-1 day-1 for 10 days) or 
3 days after the last oral dose of AmB-GCPQ 5 day course (at 5 mg kg-1 day-1 for 5 
days) were: 66.6 ± 22.9 ng mL-1, 53.5 ± 15.9 ng mL-1 and 43.8 ± 20.9 ng mL-1 
respectively; whereas the corresponding AmB kidney levels were: 1443.6 ± 662.4 ng g-
1, 578.9 ± 156.1 ng g-1 and 331.2 ± 101.1 ng g-1 respectively and plasma, kidney ratios 
were: 0.046, 0.092 and 0.132 respectively showing increased distribution to the kidney 
with Ambisome®.  
3.5. Efficacy in disseminated aspergillosis 
A low oral AmB-GCPQ dose (2.5 mg kg-1 day-1) did not increase the survival time or 
reduce the fungal burden in a murine model of disseminated aspergillosis (Figure 5a and 
5b), whereas oral AmB-GCPQ was efficacious at higher doses.  No significant 
difference in survival time, when compared to an untreated control group, was found 
between oral AmB-GCPQ (at 5 mg kg-1 day-1) and i.v. Ambisome® (at 5 mg kg-1 day-1) 
(Figure 5c).  Intravenous AMBd (at 0.8 mg kg-1 day-1) did not increase survival time 
compared to the control group (Figure 5c). In contrast to oral AMBd (at 0.8 mg kg-1 
day-1) oral AmB-GCPQ (at 5 mg kg-1 day-1) reduced tissue burden with respect to 
controls (1.3 Log10 and 2.75 Log10 in kidney and lung respectively (Figure 5d).  Higher 
oral AmB-GCPQ doses (at 7.5 or 15 mg kg-1 day-1) were statistically similar to 
Ambisome® i.v. (at 5 mg kg-1 day-1) (Figure 5e) and showed an even greater reduction 
in fungal load when compared to the lower dose of oral AmB-GCPQ (Figure 5f). No 
differences in efficacy were found between the 7.5 and 15 mg kg-1 day-1 oral doses of 
AmB-GCPQ (Figures 5e and 5f).  Animals receiving oral AmB-GCPQ gained weight 
over time at all doses, whereas mice treated with oral AMBd suffered significant weight 
loss, presumably caused by the gastrointestinal toxicity of the formulation (see 
Supplementary Information Figure S6). 
 Figure 5. Efficacy of AmB-GCPQ nanoparticles in a systemic murine model of 
aspergillosis. On the left, survival of OF-1 mice infected intravenously (i.v.) with 1x104 
CFU of A. fumigatus after treatment is shown. On the right side, scattergram of CFU g-1 
of tissue (kidney and lungs) is represented showing the median of the group by 
horizontal lines. Drugs were administered i.v. or orally by gavage (p.o.) 24h after 
infection for 10 days in the survival study or for 7 days in tissue burden study. a-b) 
Animals received liposomal AmB (AmBisome®) i.v. at 2.5 mg kg-1 day-1, amphotericin 
B deoxycolate (AMBd) i.v. at 0.5 mg kg-1 day-1 and p.o. at 2.5 mg kg-1 day-1 or AmB-
GCPQ nanoparticles  p.o. at 2.5 mg kg-1 day-1; c-d) Animals received AmBisome® i.v. 
at 5 mg kg-1 day-1, AMBd i.v. at 0.8 mg kg-1 day-1 and p.o. at 5 mg kg-1 day-1 or AmB-
GCPQ p.o. at 5 mg kg-1 day-1; e-f) Animals received AmBisome® i.v. at 5 mg kg-1 day-1, 
AMBd i.v. at 0.8 mg kg-1 day-1 or AmB-GCPQ p.o. at 7.5 and 15 mg kg-1 day-1. 
 
3.6. Efficacy in systemic candidiasis 
Although AmB levels in tissues (kidney, liver, spleen and brain) after 9 days of 
parenteral Ambisome® (at 3 mg kg-1 day-1) were significantly higher than those obtained 
after 9 days of oral AmB-GCPQ (at 5 mg kg-1 day-1) (Figure 6b), no significant 
differences were found in the reduction of fungal burden (Figure 6a and b) between both 
therapies. Oral AmB-GCPQ (at 5 mg kg-1 day-1) cleared the spleen and liver and 
reduced by 1.4 log10 the fungal load in the brain compared to control animals.  
The infected control group exhibited the highest levels of creatinine and urea as C. 
albicans infection is associated with renal failure25 (Figure 6c and d). For example, mice 
with the highest CFU in kidney (mice 1, 2 and 4) exhibited the highest urea and 
creatinine levels. Oral administration of AmB-GCPQ resulted in a reduction of urea 
levels compared to the infected control group but produced a significant increase in 
alkaline phosphatase levels (Figures 6c and h). No significant differences were observed 
among the other biochemical parameters (Figures 6e -g). 

Figure 6. PK/PD and toxicology correlation of AmB-GCPQ nanoparticles in a 
systemic murine model of candidiasis at day 10 post-infection. Treatment started 24 
h after infection and lasted for 9 days. Animals were treated with either liposomal AmB 
(AmBisome®) i.p. at 3 mg kg-1 day-1 or AmB-GCPQ p.o. at 5 mg kg-1 day-1. One group 
was included as a control. A) Scattergram of CFU g-1 of tissue (kidney, spleen, liver and 
brain) is represented showing the median of the group by horizontal lines; b) AmB 
concentration (µg g-1) in kidney, liver, spleen and brain. Statistical significant 
differences: * = p < 0.05 AmB-GCPQ versus AmBisome®; c) Urea levels (mg dL-1); d) 
Creatinine levels (mg dL-1); e) Bilirubin levels (mg dL-1); statistical significant 
differences: * = p < 0.05 AmBisome® vs infected control group; f) AST (U L-1); f) ALT 
(U L-1); f) Alkaline phosphatase (U L-1); statistical significant differences: * = p < 0.05 
AmB-GCPQ vs all the groups. Key: mouse 1 (-○-); mouse 2 (-∆-); mouse 3 (--); 
mouse 4 (-  -); mouse 5 (-□-); mean (▬). 
 
4. Discussion 
This is the first report in which orally administered nanoparticles (AmB-GCPQ) 
resulted in drug targeting to specific organs such as lung and spleen (Figures 2c, 2d and 
3b).  While both particle formulations (AmB-GCPQ and AMBd), deliver higher levels 
of drug to the liver (Figure 2b and Figure 3a), only the AmB-GCPQ formulation 
delivered drug specifically to the lung and spleen, while sparing of the organ of toxicity 
– the kidney (Figure 2e).  This targeting to key organs (essentially to the lungs, liver and 
spleen) is of benefit to the treatment of a number of infectious diseases such as visceral 
leishmaniasis (Figure 4) and systemic fungal infections (Figures 5 and 6), with a drug 
such as AmB, which is a broad spectrum anti-fungal and low resistance anti-leishmanial 
drug but which is severely nephrotoxic.  One aspect that contributes to the utility of the 
nanoparticles is the exceptional stability of the AmB-GCPQ nanoparticles.  AmB-
GCPQ nanoparticles are stable for one year on storage (Supplementary Information 
Figure S3).  AmB-GCPQ nanoparticles are formed via electrostatic interactions between 
the AmB carboxylate and GCPQ quaternary ammonium groups (Figure 1a) as well as 
via the hydrophobic attractions between the palmitoyl chains of the GCPQ molecule 
and long chain alkene groups of the AmB molecule.  The net result is a formulation of 
exceptional stability, in which nanoparticles may be reconstituted from a dry powder 
(Supplementary Information Figure S3c).    
AmB-GCPQ nanoparticles enhanced the oral absorption of AmB when compared to the 
drug alone or to the reference particulate formulation AMBd. AmB is poorly soluble in 
aqueous media (< 1 mg L-1)7 and its poor dissolution rate within the gastrointestinal 
tract will limit absorption as will its poor gut permeation, since AmB is a 
Biopharmaceutical Classification System Class IV drug with poor gut permeability as 
well as poor aqueous solubility26.  AMBd formulations will provide an increase in 
dissolution rate as AmB is encapsulated within small, high surface area deoxycholate 
micelles, however AmB-GCPQ nanoparticles will not only increase drug dissolution but 
will also be taken up via the gut enterocytes and Peyer’s patches (Figures 3c and e) thus 
solving the gut permeation problems associated with AmB.  GCPQ nanoparticles are 
positively charged and are known to be mucoadhesive12, and taken up by the gut 
enterocytes with a bioavailability of 24%13, 16 and now we also know that they are taken 
up by the Peyer’s patches (Figure 3e).  Transport from the gut associated lymphoid 
tissue via the lymphatic vessels to the systemic circulation will also increase the oral 
bioavailability of the AmB-GCPQ formulation.        
In comparison to other oral AmB lipid-based formulations that have been reported 27-29, 
AmB-GCPQ nanoparticles are able to deliver greater amounts of drug to tissues after 
administering the same oral dose (5 mg kg-1 twice daily for 5 days); drug levels are 6.6 - 
7.5 fold higher in liver, 8.6 - 10.5 fold greater in spleen, 5.2 – 6.4 fold higher in lungs 
and 2.5 fold higher in brain when compared to these other AmB lipid-based 
formulations. Furthermore this is the first study that reports an oral AmB relative 
bioavailability of 24.7%.  High levels of AmB are found in the organs of the 
reticuloendothelial system (liver, lung, spleen and bone marrow) after oral absorption of 
AmB-GCPQ (Figures 2 c – f) and this may be the result of macrophage phagocytosis of 
particles within the lymphatic vessels and systemic circulation.  GCPQ nanoparticles on 
intravenous administration are not taken up by the spleen and only very low levels (4% 
of the administered dose at the 5 minute time point)14 are found in the liver, whereas via 
the oral route GCPQ nanoparticles distribute to the spleen, liver and lung with 0.25, 2, 
0.2% of a 200 mg kg-1 dose distributing to the spleen liver and lung at the 2h time point 
respectively 13, 16.  The AmB coating on the surface of the GCPQ nanoparticles (Figure 
1b) would also contribute to uptake by macrophages as AmB is known to be cleared by 
the macrophages 7.   
The treatment of infectious diseases requires sufficient drug levels in key organs and 
although, much lower AmB concentration were recorded in target organs after oral 
administration of AmB-GCPQ nanoparticles compared to after the parenteral 
administration of AmBisome®, there were no real differences in the efficacy of oral 
AmB-GCPQ, when compared to i.v. AmBisome® (Figures 4 – 6) with respect to the 
liver, spleen and lung microorganisms.  However the lower levels of AmB found in the 
kidney on the oral administration of AmB-GCPQ did result in a poorer control of 
candidiasis fungal load in the kidney with this formulation (Figure 6a).  This also 
explains the slow recovery of kidney function (creatinine levels, Figure 6d) on oral 
administration of AmB-GCPQ.  While there were unexplained changes to the alkaline 
phosphatase levels after oral administration of AmB-GCPQ there were no significant 
differences in the other biochemical markers when AmB-GCPQ animals was compared 
to healthy controls.   
This is also the first report on the oral absorption of AmB in dogs. Absorption of AmB 
from AmB-GCPQ is superior to that seen with an oral formulation of AmBisome® 
(Figure 2g).  AmB-GCPQ is thus superior to other nanoparticle formulations such as 
AMBd and AmBisome® in rodents and dogs respectively. Interspecies differences were 
noted in the oral AmB-GCPQ plasma level time curve data.  The Cmax was lower in 
dogs when compared to mice (Figures 2a and 2g) and this could stem from differences 
in stomach pH (fasted dog stomach pH = 2.03 ± 0.59 30 and fasted mouse stomach pH = 
4.04 ± 0.2) 31 which would lead to a faster drug degradation in the dog or differences in 
bile flow (dog bile flow = 12 mL day-1 kg-1 32 and mouse bile flow = 100 mL day-1 kg-1 
32) which would lead to reduced hydrophobic drug absorption.   Plasma levels dropped 
more steeply in the mouse compared to the dog during the elimination phase (8 – 24 h 
after dosing), with a drop of 38.8% in mice and 6.7% in dogs, and this could be due to 
the faster glomerular filtration rate in dogs (glomerular filtration rate = 14 and 6 mL 
min-1 kg-1 in mice and dogs respectively 32).   
So far, marketed AmB formulations have to be parenterally administered although in 
developing countries, there are neither enough technical personal nor clinical facilities 
to allow safe parenteral i.v. administration. In such countries oral drug administration 
should clearly be the first choice format.  In this work, we have demonstrated that AmB 
accumulation in specific target organs may be achieved by the oral administration by 
AmB-GCPQ nanoparticles, resulting in high enough concentrations to elicit AmB’s 
pharmacological effect, while sparing the site of drug toxicity – the  kidney. 
 
5. Conclusions 
In summary, our work demonstrates, for the first time, that oral particle uptake and 
translocation to specific organs may be used to achieve a beneficial therapeutic 
response. We have designed an orally active nanomedicine based on an amphiphilic 
nanoparticle forming polymer (GCPQ), which achieves a relative AmB oral 
bioavailability of 24.7%.  AmB-GCPQ nanoparticles target AmB to particular organs of 
pathology and spare the site of toxicity – the kidney, resulting in effective treatments in 
preclinical disease models.  This is the first report of a therapeutic advantage stemming 
directly from particle gut uptake and translocation to key organs of pathology. AmB 
liver, spleen and lung levels after oral AmB-GCPQ administration were lower than 
those obtained with parenteral formulations, however oral AmB-GCPQ was as effective 
as the parenteral AmBisome® formulation in the treatment of visceral leishmaniasis, 
aspergillosis and systemic candidiasis animal models of these diseases.  
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Figure captions 
Figure 1. AmB-GCPQ interaction. (a) FTIR spectrum of AmB raw material, GCPQ 
and AmB-GCPQ nanoparticles after freeze drying. Key:  - stretching vibrations; δ – 
bending vibrations. (b) TEM with negative staining of AmB (8 mg mL-1)-GCPQ (40 mg 
mL-1) nanoparticles in deionized water. (c) Dissolution profile of AmB-GCPQ 
nanoparticles (-□-) versus AMBd (-■-). 
Figure 2. Pharmacokinetic studies: oral AmB translocation to major target organs. 
(a-e) Single dose oral administration of AmB formulations at 5 mg kg-1 in CD-1 
mice. Key: AmB in dextrose (-■-); AMBd (-▲-); AmB (5 mg kg-1)- GCPQ (25 mg kg-
1) formulation (-●- ). (a) AmB plasma levels (µg mL-1). (b) AmB concentration in liver 
(µg g-1).  (c) AmB concentration in spleen (µg g-1).  (d) AmB concentration in lungs (µg 
g-1).  (e) AmB concentration in kidneys (µg g-1). Statistical significant differences: * = p 
< 0.05 AmB-GCPQ versus AmB in dextrose; # = p< 0.05 AmB-GCPQ versus AMBd; + 
= p< 0.05 AmB in dextrose versus AMBd. (f) Multiple dose oral administration of 
AmB-GCPQ. AmB concentration in plasma and tissue distribution in major target 
organs after single and multiple dose administration in CD-1 mice. Key: AmB 
concentration at 24 hours after single oral administration of AmB-GCPQ formulation 
(at 5 mg kg-1) (white); AmB concentration at 24 hours following the completion of once 
daily for 5 days oral treatment course of 5 mg kg-1 of AmB-GCPQ formulation (grey); 
AmB concentration at 12 hours following the completion of twice-daily for 5 days oral 
treatment course of 5 mg kg-1 of AmB-GCPQ (black). AmB levels in bone marrow 
(BM) after single oral administration were not quantified. Statistical significant 
differences: * = p < 0.05 versus oral single dose administration and # = p< 0.05 
mutidose once-daily versus multidose twice-daily administration. (g) AmB oral 
administration in beagles. Key: AmB plasma concentration (mean ±SD) versus time 
profile after a single oral administration of AmBisome® (4 mg kg-1) (-♦-) and AmB (4 
mg kg-1)- GCPQ (20 mg kg-1) nanoparticles (-■-) in beagles.  AmB plasma 
concentration at 48 hours after orally administered AmBisome® was below the 
quantification limit of our method (15 ng mL-1). Statistical significant differences: * = p 
< 0.05 AmB-GCPQ versus AmBisome®. (h) AmB oral bioavailability. AmB plasma 
concentration (mean ±SD) versus time profile after oral (-●-) and iv (-■-) administration 
of AmB-GCPQ formulation at the dose of 5 and 1 mg kg-1 respectively. 
Figure 3. Multimodal multiphoton microscopy: oral AmB translocation to major 
target organs. (a) Liver. Three-dimensional multiphoton image reconstructions 
obtained from a liver sample. Two photon fluorescence (red) was used to generate 
contrast from endogenous fluorophores such as NADH, in addition to aldehyde-induced 
fluorescence from Schiff bases formed from the reaction of aldehydes reacting with the 
tissue proteins’ epsilon amino groups. Second harmonic generation provided contrast 
from collagen (blue). Contrast from deuterated particles was obtained with epi-detected 
CARS exciting the C-D resonance at 2100 cm-1 (green). The location of the deuterated 
particle signal is denoted by yellow arrows. (b) Lungs. Three-dimensional 
reconstructions of multiphoton images obtained from a lung sample. Red contrast was 
obtained from structures rich in C-H bonds, such as lipid droplets and cell membranes, 
using epi-detected CARS with the pump and Stokes beams tuned to excite the CH2 
resonance (2845 cm-1). Green contrast was obtained from deuterated particles with epi-
detected CARS exciting the C-D resonance at 2100 cm-1. (c) Small intestine. Three-
dimensional reconstructions of multiphoton images obtained from a small intestine 
sample. Two photon fluorescence (red) – exciting contrast from endogenous 
fluorophores such as NADH, in addition to aldehyde-induced fluorescence from Schiff 
bases formed from the reaction of aldehydes reacting with the tissue proteins’ epsilon 
amino groups. Green contrast was obtained from deuterated particles with epi-detected 
CARS exciting the C-D resonance at 2100 cm-1. Within the villus cross sections, it is 
possible to see deuterated GCPQ has crossed the enterocyted (ii, iii and iv). Deuterated 
GCPQ signal is also found in association with mucus above the villi’s surface in the 
three-dimensional reconstruction in (i). (d) Brunner’s gland. Three-dimensional 
multiphoton image reconstruction of Brunner’s glands. Red contrast was obtained from 
structures rich in C-H bonds, such as lipid droplets and cell membranes, using epi-
detected CARS with the pump and Stokes beams tuned to excite the CH2 resonance 
(2845 cm-1). Green contrast was obtained from deuterated particles with epi-detected 
CARS exciting the C-D resonance at 2100 cm-1. Blue contrast arises from SHG of 
collagen within the sample. (e) Peyer’s patch. i) Transmitted light image at low 
magnification, illustrating a Peyer’s patch and surrounding villi. ii – vi) Epi-detected 
CARS image composites (red shows contrast from the CH stretch obtained with the 
pump and Stokes beams tuned to 2855 cm-1, green shows contrast from the CD stretch 
obtained with the pump and Stokes beams tuned to 2100 cm-1.) ii and iii were taken at 
the surface of the Peyer’s patch, with M-cells and goblet cells marked with ‘M’ and ‘G’ 
respectively on B. iv was taken 14 microns below the surface, in the region outlined 
with a yellow box on iii. The cell outlined with a yellow box in iv is shown in more 
detail in v and vi, in three-dimensional composites of the CARS depth stack, illustrating 
the distribution of dGCPQ within this cell.  
Figure 4. Antileismanial activity of oral AmB-GCPQ nanoparticles in L. infantum-
infected BALB/c mice. All treatments started 24 days post-infection. Groups of 
animals (n = 8) received either AmBisome® i.p. at a single dose of 5 mg kg-1 body 
weight or orally AmB-GCPQ formulation at 5 mg kg-1 once-daily for 10 consecutive 
days. The parasitic burden was estimated by the limit dilution assay. Key: percentage of 
suppression of parasite replication in liver (grey) and spleen (white). Data are expressed 
as mean ± SD. Statistical significant differences (p < 0.05) were not found between both 
regimens. 
Figure 5. Efficacy of AmB-GCPQ nanoparticles in a systemic murine model of 
aspergillosis. On the left, survival of OF-1 mice infected intravenously (i.v.) with 1x104 
CFU of A. fumigatus after treatment is shown. On the right side, scattergram of CFU g-1 
of tissue (kidney and lungs) is represented showing the median of the group by 
horizontal lines. Drugs were administered i.v. or orally by gavage (p.o.) 24h after 
infection for 10 days in the survival study or for 7 days in tissue burden study. a-b) 
Animals received liposomal AmB (AmBisome®) i.v. at 2.5 mg kg-1 day-1, amphotericin 
B deoxycolate (AMBd) i.v. at 0.5 mg kg-1 day-1 and p.o. at 2.5 mg kg-1 day-1 or AmB-
GCPQ nanoparticles  p.o. at 2.5 mg kg-1 day-1; c-d) Animals received AmBisome® i.v. 
at 5 mg kg-1 day-1, AMBd i.v. at 0.8 mg kg-1 day-1 and p.o. at 5 mg kg-1 day-1 or AmB-
GCPQ p.o. at 5 mg kg-1 day-1; e-f) Animals received AmBisome® i.v. at 5 mg kg-1 day-1, 
AMBd i.v. at 0.8 mg kg-1 day-1 or AmB-GCPQ p.o. at 7.5 and 15 mg kg-1 day-1. 
Figure 6. PK/PD and toxicology correlation of AmB-GCPQ nanoparticles in a 
systemic murine model of candidiasis at day 10 post-infection. Treatment started 24 
h after infection and lasted for 9 days. Animals were treated with either liposomal AmB 
(AmBisome®) i.p. at 3 mg kg-1 day-1 or AmB-GCPQ p.o. at 5 mg kg-1 day-1. One group 
was included as a control. A) Scattergram of CFU g-1 of tissue (kidney, spleen, liver and 
brain) is represented showing the median of the group by horizontal lines; b) AmB 
concentration (µg g-1) in kidney, liver, spleen and brain. Statistical significant 
differences: * = p < 0.05 AmB-GCPQ versus AmBisome®; c) Urea levels (mg dL-1); d) 
Creatinine levels (mg dL-1); e) Bilirubin levels (mg dL-1); statistical significant 
differences: * = p < 0.05 AmBisome® vs infected control group; f) AST (U L-1); f) ALT 
(U L-1); f) Alkaline phosphatase (U L-1); statistical significant differences: * = p < 0.05 
AmB-GCPQ vs all the groups. Key: mouse 1 (-○-); mouse 2 (-∆-); mouse 3 (--); 
mouse 4 (-  -); mouse 5 (-□-); mean (▬). 
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